| Company | Value | Change | %Change |
|---|
Under the agreement signed in September 2023, Glenmark in-licensed the product from Cosmo Pharmaceuticals for distribution across Europe and South Africa.
Winlevi is used to treat acne vulgaris in patients aged 12 and above. It is the first topical acne treatment in nearly 40 years to feature a first-in-class mechanism of action, marking a breakthrough in dermatology.
The MHRA approval represents a significant milestone for both companies, reinforcing their commitment to expanding their dermatology portfolio. Acne vulgaris affects millions worldwide, causing both physical discomfort and psychological distress, Glenmark and Cosmo Pharma said in a press release.Acne vulgaris is one of the most prevalent skin conditions, impacting over 90% of the global population.
Also read: Glenmark Pharmaceuticals gets ₹121.25 crore GST demand, plans to appeal
“We are excited to receive this approval and bring Winlevi to the UK market, offering patients an innovative and effective acne treatment. This approval by the MHRA represents a major step in our mission to enhance dermatology care,” said Christoph Stoller, President & Business Head – Europe and Emerging Markets, Glenmark Pharmaceuticals.
On Monday, Glenmark Pharma’s stock opened marginally lower at ₹1,539.85 apiece on the BSE and slipped 1.3% to an intraday low of ₹1,519.50. At around 1:23 pm, the stock was trading 1.26% lower at ₹1,520.75, while the benchmark Sensex was down 0.87% at 77,185.84 points.
(Edited by : Shersh Kapoor)
